These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18825844)

  • 21. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.
    Green C; Linch DC; Gale RE
    Br J Haematol; 2008 Jul; 142(3):423-6. PubMed ID: 18537976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
    Löwenberg B
    N Engl J Med; 2008 May; 358(18):1960-2. PubMed ID: 18450608
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.
    Tosić N; Stojiljković M; Colović N; Colović M; Pavlović S
    Cancer Genet Cytogenet; 2009 Sep; 193(2):98-103. PubMed ID: 19665070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular classification of acute myeloid leukemia: are we there yet?
    Radich JP
    J Clin Oncol; 2008 Oct; 26(28):4539-41. PubMed ID: 18559871
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
    Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
    Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
    Oveland E; Gjertsen BT; Wergeland L; Selheim F; Fladmark KE; Hovland R
    Leuk Res; 2009 Feb; 33(2):276-87. PubMed ID: 18691757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of acute myeloid leukemia.
    Döhner K; Döhner H
    Haematologica; 2008 Jul; 93(7):976-82. PubMed ID: 18591623
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparing apples and oranges in normal karyotype acute myeloid leukemia.
    Medeiros BC
    J Clin Oncol; 2009 Jan; 27(3):474; author reply 474-6. PubMed ID: 19075259
    [No Abstract]   [Full Text] [Related]  

  • 31. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
    Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
    Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Acute myeloid leukemia].
    Watanabe R
    Rinsho Ketsueki; 2009 Mar; 50(3):154-9. PubMed ID: 19352081
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical progress in acute myeloid leukemia. Preface.
    Rowe JM
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):597-9. PubMed ID: 19041598
    [No Abstract]   [Full Text] [Related]  

  • 36.
    Loo S; Wei AH
    Haematologica; 2022 Apr; 107(4):783-784. PubMed ID: 34348456
    [No Abstract]   [Full Text] [Related]  

  • 37. Gene expression profiling in acute myeloid leukaemia (AML).
    Bacher U; Kohlmann A; Haferlach C; Haferlach T
    Best Pract Res Clin Haematol; 2009 Jun; 22(2):169-80. PubMed ID: 19698926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
    Schlenk RF; Döhner K
    Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
    Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
    Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.